Targeting the Wnt/β-catenin pathway in human osteosarcoma cells

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Aberrant activation of Wnt signaling is linked to human osteosarcoma development.
• This pathway presents a potential therapeutic target for osteosarcoma treatment.

Purpose of the Study:

• To investigate the necessity of Wnt activation for osteosarcoma growth, colony formation, invasion, and metastasis.
• To evaluate the therapeutic potential of Wnt/β-catenin pathway inhibition in osteosarcoma.

Main Methods:

• Treatment of human osteosarcoma cells (143B and SJSA-1) with the Wnt/β-catenin inhibitor PRI-724.
• Analysis of protein levels for active-β-catenin and Wnt target Cyclin D1.
• Assessment of cell proliferation, migration, invasion, and colony formation.
• Bioinformatic analysis of next-generation sequencing data for Wnt pathway somatic mutations and gene expression.

Main Results:

• Increased endogenous active-β-catenin protein levels were observed in five human osteosarcoma cell lines.
• PRI-724 treatment inhibited proliferation, migration, invasion, and colony formation in osteosarcoma cells.
• Wnt signaling suppression was confirmed by decreased Cyclin D1 levels.
• Analysis revealed somatic mutations and upregulated gene expression in Wnt pathway components, indicating pathway activation.

Conclusions:

• Wnt/β-catenin signaling plays a critical role in the pathogenesis and growth of human osteosarcoma.
• Wnt inhibitors like PRI-724 demonstrate significant therapeutic potential for treating human osteosarcoma.